Myriad Genetics Inc. announced that six abstracts will be presented at the 2026 ASCO Genitourinary Cancers Symposium (Feb. 26–28) on its Precise MRD molecular residual disease test, Prolaris prostate cancer prognostic test, and MyRisk hereditary cancer test. The presentations include interim and preliminary results from studies evaluating whole-genome sequencing–based ctDNA detection in urothelial cancer and renal cell carcinoma, a phase I/II trial (CONSOLIDATE) combining radiotherapy with enfortumab vedotin in locally advanced bladder cancer with paired ctDNA and utDNA analyses, an individual participant data meta-analysis of 14 Prolaris studies involving more than 8,000 patients, and an analysis of germline variant prevalence by Gleason score and NCCN risk grouping in localized prostate cancer. Results have not yet been presented and are scheduled for presentation at the meeting.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Myriad Genetics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202602240900PRIMZONEFULLFEED9659575) on February 24, 2026, and is solely responsible for the information contained therein.